Drug Delivery System in the Treatment of Diabetes Mellitus

doi:10.3389/fbioe.2020.00880

	Drug Delivery System in the Treatment of Diabetes Mellitus
	Zhao, Ruichen 1,2; Lu, Zhiguo 1,2; Yang, Jun 1; Zhang, Liqun 3; Li, Yan 1; Zhang, Xin 1
刊名	FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
	2020-07-29
卷号	8 页码:16
关键词	diabetes mellitus drug delivery insulin gene therapy nanoparticle
ISSN号	2296-4185
DOI	10.3389/fbioe.2020.00880
英文摘要	Diabetes mellitus has been described as a chronic endocrine and metabolic disease, which is characterized by hyperglycemia and the coexistence of multiple complications. At present, the drugs widely applied in clinical treatment of diabetes mellitus mainly include insulin, insulin analogs, non-insulin oral hypoglycemic drugs and genetic drugs. Nevertheless, there is still no complete therapy strategy for diabetes mellitus management by far due to the intrinsic deficiencies of drugs and limits in administration routes such as the adverse reactions caused by long-term subcutaneous injection and various challenges in oral administration, such as enzymatic degradation, chemical instability and poor gastrointestinal absorption. Therefore, it is remarkably necessary to develop appropriate delivery systems and explore complete therapy strategies according to the characters of drugs and diabetes mellitus. Delivery systems have been found to be potentially beneficial in many aspects for effective diabetes treatment, such as improving the stability of drugs, overcoming different biological barriersin vivoto increase bioavailability, and acting as an intelligent automatized system to mimic endogenous insulin delivery and reduce the risk of hypoglycemia. This review aims to provide an overview related with the research advances, development trend of drug therapy and the application of delivery systems in the treatment diabetes mellitus, which could offer reference for the application of various drugs in the field of diabetes mellitus treatment.
资助项目	National High Technology Research and Development Program[2016YFA0200303] ; Beijing Natural Science Foundation[L172046] ; Beijing Natural Science Foundation[2192057] ; National Natural Science Foundation of China[31771095] ; National Natural Science Foundation of China[21875254] ; National Natural Science Foundation of China[21905283]
WOS关键词	TYROSINE-PHOSPHATASE 1B ; PANCREATIC ALPHA-CELLS ; ORAL DELIVERY ; THERAPEUTIC TARGET ; OXIDATIVE STRESS ; GENE-THERAPY ; BETA-CELLS ; INSULIN ; GLUCOSE ; INHIBITION
WOS研究方向	Biotechnology & Applied Microbiology ; Science & Technology - Other Topics
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000561447900001
资助机构	National High Technology Research and Development Program ; Beijing Natural Science Foundation ; National Natural Science Foundation of China
内容类型	期刊论文
源URL	[http://ir.ipe.ac.cn/handle/122111/41742]
专题	中国科学院过程工程研究所
通讯作者	Zhang, Liqun; Li, Yan; Zhang, Xin
作者单位	1.Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing, Peoples R China 2.Univ Chinese Acad Sci, Beijing, Peoples R China 3.Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Zhao, Ruichen,Lu, Zhiguo,Yang, Jun,et al. Drug Delivery System in the Treatment of Diabetes Mellitus[J]. FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY,2020,8:16.
APA	Zhao, Ruichen,Lu, Zhiguo,Yang, Jun,Zhang, Liqun,Li, Yan,&Zhang, Xin.(2020).Drug Delivery System in the Treatment of Diabetes Mellitus.FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY,8,16.
MLA	Zhao, Ruichen,et al."Drug Delivery System in the Treatment of Diabetes Mellitus".FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY 8(2020):16.